Clinical Trial Info

A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Authored by
Staff

This is a phase IIb clinical trial to evaluate the safety and immunogenicity of Ad5-nCoV developed by Cansino and Beijing Institute of Biotechnology in health people aged 6 years old and above.

The study will be a double-blind, placebo-controlled trial with participants randomly allocated 2:1 to placebo and experimental vaccine.

The immunization schedule is two doses intramuscular injections (deltoid).